Financial reports
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
10-Q
2019 Q1
Quarterly report
10 May 19
10-K
2018 FY
Annual report
13 Mar 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18
10-K/A
2017 FY
Annual report (amended)
30 Apr 18
10-K
2017 FY
Annual report
16 Mar 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
Current reports
8-K
Bankruptcy or Receivership
20 Apr 20
8-K
In the United States Bankruptcy Court for the District of Delaware
14 Apr 20
8-K
Other Events
18 Feb 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Jan 20
8-K
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
27 Dec 19
8-K
Other Events
6 Nov 19
8-K
Other Events
24 Oct 19
8-K
Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director
3 Sep 19
8-K
Melinta Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update
9 Aug 19
8-K
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update
16 Jul 19
Registration and prospectus
SC TO-T/A
Third party tender offer statement (amended)
24 Jun 20
SC TO-T
Third party tender offer statement
12 Jun 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-3DPOS
Registration of securities, dividend or interest reinvestment plans, immediately effective (post-effective amendment)
20 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Apr 20
Proxies
DEF 14A
Definitive proxy
30 Apr 19
DEFA14A
Additional proxy soliciting materials
13 Feb 19
DEFA14A
Additional proxy soliciting materials
4 Feb 19
DEFR14A
Revised proxy
28 Jan 19
DEFA14A
Additional proxy soliciting materials
16 Jan 19
PRER14A
Preliminary revised proxy
15 Jan 19
DEFA14A
Additional proxy soliciting materials
2 Jan 19
DEFA14A
Additional proxy soliciting materials
19 Dec 18
DEFA14A
Additional proxy soliciting materials
19 Dec 18
DEFA14A
Additional proxy soliciting materials
19 Dec 18
Other
CT ORDER
Confidential treatment order
26 Dec 18
CT ORDER
Confidential treatment order
11 Jun 18
EFFECT
Notice of effectiveness
6 Feb 18
CORRESP
Correspondence with SEC
2 Feb 18
UPLOAD
Letter from SEC
2 Feb 18
EFFECT
Notice of effectiveness
24 Jan 18
EFFECT
Notice of effectiveness
24 Jan 18
EFFECT
Notice of effectiveness
24 Jan 18
CORRESP
Correspondence with SEC
23 Jan 18
CORRESP
Correspondence with SEC
23 Jan 18
Ownership
3
Ryan Lococo
25 Oct 19
3
Susan Blum
25 Oct 19
3
Jennifer A Sanfilippo
13 Sep 19
SC 13D/A
Melinta Therapeutics, Inc. /New/
12 Aug 19
SC 13G/A
Melinta Therapeutics, Inc. /New/
10 Jul 19
4
JOHN JOHNSON
2 Jul 19
SC 13D/A
Melinta Therapeutics, Inc. /New/
2 Jul 19
4
JOHN JOHNSON
26 Jun 19
4
Kevin Ferro
12 Jun 19
4
BRUCE DOWNEY
12 Jun 19